-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: keymaster@town.hall.org Originator-Key-Asymmetric: MFkwCgYEVQgBAQICAgADSwAwSAJBALeWW4xDV4i7+b6+UyPn5RtObb1cJ7VkACDq pKb9/DClgTKIm08lCfoilvi9Wl4SODbR1+1waHhiGmeZO8OdgLUCAwEAAQ== MIC-Info: RSA-MD5,RSA, VkzSZjusuMJaan2VbVcy0lyngp49XytAZMHWud0OILpmnI8YeaPiwB5t9NC9zAkO 8C3KkEYngHNk3yyGrsGzGA== 0000217028-95-000006.txt : 19950613 0000217028-95-000006.hdr.sgml : 19950613 ACCESSION NUMBER: 0000217028-95-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19950222 ITEM INFORMATION: Changes in control of registrant FILED AS OF DATE: 19950308 SROS: NYSE FILER: COMPANY DATA: COMPANY CONFORMED NAME: RHONE POULENC RORER INC CENTRAL INDEX KEY: 0000217028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 231699163 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05851 FILM NUMBER: 95519258 BUSINESS ADDRESS: STREET 1: 500 ARCOLA RD STREET 2: P O BOX 1200 CITY: COLLEGEVILLE STATE: PA ZIP: 19426 BUSINESS PHONE: 2154548000 FORMER COMPANY: FORMER CONFORMED NAME: RORER GROUP INC DATE OF NAME CHANGE: 19900731 FORMER COMPANY: FORMER CONFORMED NAME: RORER AMCHEM INC DATE OF NAME CHANGE: 19770604 8-K 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 22, 1995 ----------------------------------------------------------------- Rhone-Poulenc Rorer Inc. ----------------------------------------------------------------- (Exact name of registrant as specified in its charter) Pennsylvania 1-5851 23-1699163 -------------------------------------------------------------------------- (State or other juris- (Commission (IRS Employer diction of incorporation) File Number) Identification No.) 500 Arcola Road, Collegeville, PA 19426 --------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (610)454-8000 ---------------------- ------------------------------------------------------------------------ (Former name or former address, if changed since last report) Item 5. Other Events - ------------------------------- As announced in the attached press release, on February 22, 1995, Rhone- Poulenc Rorer's Armour Pharmaceutical Company subsidiary and Behringwerke AG, a subsidiary of Hoechst AG, signed an agreement to form a global joint venture dedicated to the plasma proteins business. Under the terms of the agreement, both companies will contribute to the joint venture all the assets of their respective plasma operations in exchange for a 50% interest in the new entity. The agreement is subject to U.S. and European regultory approvals. Item 7. Exhibits - ----------------------------- (c) Exhibit 20 - Armour Pharmaceutical Company and Behringwerke AG press release dated February 23, 1995. 2 SIGNATURES ---------------------- Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHONE-POULENC RORER INC. ---------------------------------------- (registrant) Dated: March 8, 1995 By: /s/Richard B. Young -------------------------------------------- Richard B. Young Vice President and Secretary 3 EXHIBIT INDEX ----------------------- (20) Armour Pharmaceutical Company and Behringwerke AG press release dated February 23, 1995. 4 EX-20 2 EXHIBIT 20 A(company insignia) BEHRING(company insignia) ARMOUR Behringwerke AG PHARMACEUTICAL Postfach 1140 COMPANY FOR IMMEDIATE RELEASE D 35001 Marburg Collegeville, PA 19426 ARMOUR AND BEHRINGWERKE TO CREATE A JOINT VENTURE. Pennsylvania, USA and Marburg, Germany - February 23, 1995 - Armour Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer Inc. (NYSE:RPR), and Behringwerke AG, a subsidiary of Hoechst AG, announced the signing of an agreement to form a joint venture in the highly competitive field of plasma proteins. Under the terms of the agreement, both companies will contribute to the joint venture all of the assets of their respective plasma operations in exchange for a one-half equity interest in a new entity. A priority of the joint venture would be to increase the availability of innovative products through its enhanced capacity to invest in research and development. Armour and Behringwerke have complementary product lines, that if combined, would provide a broad range of life-saving therapies to patients throughout the world. The companies also complement each other geographically as Armour has a strong presence in the United States, while Behringwerke is principally in Europe and Japan. Over the last decade, Armour and Behringwerke have both developed important product and technology innovations in the plasma protein field. Both companies also use liquid pasteurization for viral inactivation and have active programs in recombinant and gene therapy research. The agreement is subject to regulatory approval by agencies of the United States government and the European Union. Behringwerke is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of plasma proteins, vaccines and diagnostic products. Armour is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of plasma proteins. Contacts: Armour Behringwerke AG: Beth Leahy: (610)454-3879 Wolfgang Faust: (49)6421 39 4189 Catherine LeLouarn: (33)1.40.91.4168 5 -----END PRIVACY-ENHANCED MESSAGE-----